Andrew R Crawford1, Naji Alamuddin1, Anastassia Amaro2. 1. Division of Endocrinology, Diabetes and Metabolism, Perelman School of Medicine, and Penn Metabolic Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. 2. Division of Endocrinology, Diabetes and Metabolism, Perelman School of Medicine, and Penn Metabolic Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104, USA. Anastassia.Amaro@uphs.upenn.edu.
Abstract
PURPOSE OF REVIEW: We review recent studies discussing the impact of pharmacologic agents for weight loss on clinical cardiovascular events, as well as cardiometabolic risk factors. RECENT FINDINGS: Pharmacotherapy with current FDA-approved medications for weight loss can significantly improve known risk factors for the development of cardiovascular disease such as hypertension, hyperlipidemia, insulin resistance, inflammatory biomarkers, and the quantity of visceral fat, as well as non-alcoholic fatty liver disease. However, data regarding the actual reduction in clinical cardiovascular events with the use of weight loss medications is scarce. Pharmacotherapy for weight loss may have additional benefit in optimizing patient's cardiometabolic comorbidities and improving their clinical cardiovascular outcomes, but each drug should be carefully selected based upon individual patient characteristics.
PURPOSE OF REVIEW: We review recent studies discussing the impact of pharmacologic agents for weight loss on clinical cardiovascular events, as well as cardiometabolic risk factors. RECENT FINDINGS: Pharmacotherapy with current FDA-approved medications for weight loss can significantly improve known risk factors for the development of cardiovascular disease such as hypertension, hyperlipidemia, insulin resistance, inflammatory biomarkers, and the quantity of visceral fat, as well as non-alcoholic fatty liver disease. However, data regarding the actual reduction in clinical cardiovascular events with the use of weight loss medications is scarce. Pharmacotherapy for weight loss may have additional benefit in optimizing patient's cardiometabolic comorbidities and improving their clinical cardiovascular outcomes, but each drug should be carefully selected based upon individual patient characteristics.
Entities:
Keywords:
Heart disease; Metabolic syndrome; Obesity; Weight loss medications
Authors: Patrick M O'Neil; Steven R Smith; Neil J Weissman; Meredith C Fidler; Matilde Sanchez; Jinkun Zhang; Brian Raether; Christen M Anderson; William R Shanahan Journal: Obesity (Silver Spring) Date: 2012-03-16 Impact factor: 5.002
Authors: Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand Journal: Lancet Date: 2005-11-05 Impact factor: 79.321
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: Steven E Nissen; Kathy E Wolski; Lisa Prcela; Thomas Wadden; John B Buse; George Bakris; Alfonso Perez; Steven R Smith Journal: JAMA Date: 2016-03-08 Impact factor: 56.272
Authors: M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield Journal: JAMA Date: 1999-01-20 Impact factor: 56.272
Authors: Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding Journal: N Engl J Med Date: 2015-07-02 Impact factor: 91.245
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Karen Alejandra Méndez-Lara; Núria Farré; David Santos; Andrea Rivas-Urbina; Jari Metso; José Luis Sánchez-Quesada; Vicenta Llorente-Cortes; Teresa L Errico; Enrique Lerma; Matti Jauhiainen; Jesús M Martín-Campos; Núria Alonso; Joan Carles Escolà-Gil; Francisco Blanco-Vaca; Josep Julve Journal: Int J Mol Sci Date: 2019-02-02 Impact factor: 5.923